WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY ANNOUNCE FLU VACCINE AGREEMENT
WYETH-AYERST LABORATORIES AND THE LIPOSOME COMPANY
ANNOUNCE FLU VACCINE AGREEMENT
PRINCETON, N.J., Jan. 23 /PRNewswire/ -- Wyeth-Ayerst Laboratories, a division of American Home Products Corp. (NYSE: AHP) and the Liposome Company, Inc. (NASDAQ: LIPO) announced today an agreement to develop a human liposomal influenza vaccine, based on positive results seen in early animal tests conducted by the companies. The vaccine, more commonly known as a "flu shot," will incorporate a liposomal adjuvant invented and patented by the Liposome Company. The purpose of an adjuvant is to boost the protective effect of the vaccine, in this case against influenza infections.
In experiments conducted by Wyeth-Ayerst and Liposome, animals injected with an influenza vaccine containing the liposomal adjuvant had much greater immune responses than animals receiving vaccines without the liposomal adjuvant. It is believed that the level of immune response is a good indicator of how well the vaccine might work in protecting against influenza infections. The experiments indicated that the protective effect with the vaccine containing the liposomal adjuvant would be far greater than with conventional vaccines, both in terms of the magnitude of the response and also its duration.
Having successfully established the feasibility of an improved influenza vaccine, the companies are initiating a development program which will ultimately lead to product registration and marketing. Wyeth-Ayerst will conduct this development effort.
"We are very excited by these early results of the animal tests of a liposomal-adjuvanted influenza vaccine," said Fred Hassan, president of Wyeth-Ayerst. "This agreement is a good fit with our corporate commitment to work with leading companies to develop a new generation of superior vaccines. We are looking forward to building a long-term relationship with the Liposome Company."
Charles A. Baker, chairman and chief executive officer of the Liposome Company said, "Wyeth-Ayerst, as a world leader in the development, manufacturing and marketing of influenza and other vaccines, is in an ideal position to maximize the potential of our liposomal vaccine adjuvant system. We are confident that with Wyeth- Ayerst's resources behind it, this project should move ahead rapidly."
Wyeth-Ayerst Laboratories is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic disease therapies, CNS, anti- inflammatory agents, vaccines and infant nutritionals.
The largest company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, the Liposome Company selectively develops proprietary parenteral pharmaceuticals for the treatment, prevention and diagnosis of life-threatening illnesses.
/CONTACT: Anne Van Lent, senior vice president of the Liposome Company, 609-452-7060, or Audrey Ashby of Wyeth-Ayerst Laboratories, 215-971-5823/
(LIPO AHP) CO: Liposome Company, Inc.; Wyeth-Ayerst Laboratories ST: New Jersey, Pennsylvania IN: MTC SU: PS -- NY004 -- 2627 01/23/92 09:00 EST